8-K: MetaVia Announces Positive DA-1726 Data, Advances to Phase 2

MetaVia Inc. reported statistically significant reductions in uric acid levels from its Phase 1 trial of DA-1726, reinforcing its potential for liver-related cardiometabolic diseases.

Summary

• MetaVia Inc. announced additional positive data from its Phase 1 clinical trial of DA-1726, an OXM analog targeting GLP-1 and glucagon receptors.
• The trial demonstrated a statistically significant 1.47 mg/dL placebo-adjusted reduction in serum uric acid levels after 16 weeks of treatment in adults with obesity.
• This adds to previously reported results showing a 68.1% placebo-adjusted reduction in liver fat, 13.5% placebo-adjusted weight loss, and a 0.44 absolute percentage-point reduction in HbA1c.
• All participants with baseline steatosis achieved liver fat levels below 5% by Day 109.
• The company is advancing DA-1726 towards a planned Phase 2 study in Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD) in the second half of 2027.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with statistically significant data supporting the efficacy of DA-1726 and a clear path forward for clinical development.

Positives

• Statistically significant placebo-adjusted reduction of 1.47 mg/dL in serum uric acid levels (p<0.001).
• All subjects with baseline steatosis achieved liver fat levels below 5% by Day 109.
• Previously reported 68.1% placebo-adjusted reduction in liver fat (p<0.001).
• Previously reported 13.5% placebo-adjusted weight loss (p<0.001).
• Previously reported 0.44 absolute percentage-point reduction in HbA1c (p=0.006).
• DA-1726 targets both GLP-1 and glucagon receptors, offering a dual mechanism for cardiometabolic diseases.
• The drug is designed for once-weekly subcutaneous administration.

Negatives

• The interim analysis included a small sample size (15 participants treated with DA-1726 and 4 receiving placebo).
• The company has a history of net losses and relies on existing cash and potential future capital raises.

Risks

• Actual events or results may differ materially from forward-looking statements.
• The company's ability to execute its commercial strategy and obtain regulatory approval.
• The timeline for initiating and completing clinical trials.
• Potential negative interactions between DA-1726 and other treatments.
• The sufficiency of existing cash to fund operations and the need to raise additional capital.
• Adverse global economic conditions.

Future Outlook

MetaVia expects to report full data from Part 3A and Part 3B of its Phase 1 trial in the first quarter of 2027. The company is planning a 48-week, non-biopsy Phase 2 study in up to 150 subjects with MetALD and ALD, targeted to begin in the second half of 2027.

Management Comments

• "These additional findings further strengthen the metabolic profile emerging for DA-1726 and provide another encouraging signal as we advance its development in liver-related cardiometabolic diseases."
• "The statistically significant reduction in uric acid is particularly noteworthy given that participants entered the study with mean levels already within the normal range."
• "Elevated uric acid has been associated with liver fat accumulation, insulin resistance and alcohol consumption, making these findings particularly relevant to our focus on MetALD and ALD."
• "Combined with the previously reported significant reductions in liver fat, body weight and HbA1c, these results reinforce our belief that DA-1726 has the potential to deliver benefits beyond weight loss alone."
• "We believe the dual GLP-1 and glucagon receptor agonism of DA-1726, together with the robust effects observed across multiple metabolic parameters, provides a compelling foundation for further clinical development."

Industry Context

StockSavvy.ai notes that the development of dual GLP-1/GCGR agonists like DA-1726 is a significant trend in the pharmaceutical industry, aiming to address multiple facets of cardiometabolic diseases beyond just weight loss, including liver fat reduction and improved glycemic control.

Comparison to Industry Standards

• The reported 68.1% placebo-adjusted reduction in liver fat is a substantial improvement, potentially positioning DA-1726 as a leading candidate for NASH/MASH and related liver conditions.
• The 13.5% placebo-adjusted weight loss is comparable to other leading GLP-1 agonists, indicating strong efficacy in this area.
• The statistically significant reduction in uric acid, even from normal baseline levels, is a novel finding for this class of drugs and could offer additional therapeutic benefits, differentiating it from single-receptor agonists.

Stakeholder Impact

• Shareholders: Positive impact expected from promising clinical trial data and advancement of drug candidates, potentially increasing company valuation.
• Patients: Potential for new therapeutic options for liver-related cardiometabolic diseases, offering benefits beyond weight loss.
• Healthcare Providers: New treatment options to manage complex conditions like MetALD and ALD.

Next Steps

• Report full data from Phase 1 Part 3A and Part 3B trials in Q1 2027.
• Initiate a 48-week, non-biopsy Phase 2 study in MetALD and ALD in the second half of 2027.
• Continue development of vanoglipel (DA-1241) in combination with resmetirom for MASH, with a Phase 2a study targeted for H1 2027.

Key Dates

Recommendation

The data presented is positive and supports the continued development of DA-1726. However, the company is still in the clinical trial phase with a long road to market and a history of net losses. Further data from Phase 2 trials and clarity on regulatory pathways are needed before a stronger recommendation can be made. The company's reliance on future capital raises also introduces risk.

Keywords

DA-1726, Oxyntomodulin, GLP-1 receptor agonist, Glucagon receptor agonist, Liver disease, Metabolic dysfunction, Obesity, Uric acid